Do you give bisphosphonates after completing adjuvant anti-HER2 therapy and chemotherapy for HER2+ breast cancer to reduce the risk of recurrence?

Bisphosphonates and the RANK-ligand inhibitor, denosumab, are bone-modifying agents that are indicated to decrease the risk of bone fragility fractures in at-risk populations without cancer, and to decrease pain and complications related to metastatic bone disease. In the adjuvant setting for postme...

I think the evidence is pretty strong showing that bisphosphonates decrease the risk of recurrence in postmenopausal women with breast cancer, and there does not appear to be subgroups that do not benefit. However, the precise benefit of adjuvant bisphosphonates in HER2 positive patients treated wit...